The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Open accessAbstract
In order to meet the high energy demand, a metabolic reprogramming occurs in cancer cells. Its role is crucial in promoting tumor survival. Among the substrates in demand, oxygen is fundamental for bioenergetics. Nevertheless, tumor microenvironment is frequently characterized by low-oxygen conditions. Hypoxia-inducible factor 1 (HIF-1) is a pivotal modulator of the metabolic reprogramming which takes place in hypoxic cancer cells. In the hub of cellular bioenergetics, mitochondria are key players in regulating cellular energy. Therefore, a close crosstalk between mitochondria and HIF-1 underlies the metabolic and functional changes of cancer cells. Noteworthy, HIF-1 represents a promising target for novel cancer therapeutics. In this review, we summarize the molecular mechanisms underlying the interplay between HIF-1 and energetic metabolism, with a focus on mitochondria, of hypoxic cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., & Semenza, G. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800102200 · Cited by 1,601
RetractedRETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
RetractedLee, K., Qian, D. Z., Rey, S., Wei, H., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812801106 · Cited by 289
RetractedSamanta, D., Park, Y., Andrabi, S. A., Shelton, L. M., Gilkes, D. M., & Semenza, G. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0530 · Cited by 238
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative Stress
Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., Calfon, M., Sadri, N., Yun, C., Popko, B., Paules, R., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00105-9 · Cited by 3,323
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“The enzyme requires molecular oxygen, α-ketoglutarate (αKG), and Fe(II) and generates succinate and CO2 as by-products (Figure 2) [29].”
BackgroundTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood, T. M., Melendez, J. A., Rodriguez, A. M., & Schumacker, P. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001914200 · Cited by 2,000
The multifaceted roles of fatty acid synthesis in cancer
Röhrig, F., & Schulze, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.89 · Cited by 1,651
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550 · cited 3×
“Another HIF-1α hydroxylation reaction occurs in well-oxygenated cells: the hydroxylase called factor inhibiting HIF-1 (FIH-1), a Fe(II)- and αKG-dependent dioxygenase, hydroxylates N803 with consequent disturbance of the interaction between HIF-1α and transcription coactivators CBP/p300 (Figure 2) [14,30].”
BackgroundBellot, G., Garcia-Medina, R., Gounon, P., Chiche, J., Roux, D., Pouysségur, J., & Mazure, N. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00166-09 · Cited by 1,501
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., & Semenza, G. L. (2011) · Cell · doi:10.1016/j.cell.2011.03.054 · Cited by 1,463
Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
Lactate Metabolism in Human Lung Tumors
Faubert, B., Li, K. Y., Cai, L., Hensley, C. T., Kim, J., Zacharias, L. G., Yang, C., Do, Q. N., Doucette, S., Burguete, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.019 · Cited by 1,343
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways
Fearon, K. C. H., Glass, D. J., & Guttridge, D. C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.06.011 · Cited by 1,205
Huang, L. E., Arany, Z., Livingston, D. M., & Bunn, H. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.32253 · Cited by 1,190
Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J.-K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., et al. (2011) · Science · doi:10.1126/science.1211485 · Cited by 1,190
ERK signalling: A master regulator of cell behaviour, life and fate
Lavoie, H., Gagnon, J., & Therrien, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0255-7 · Cited by 1,185
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · cited 1×
“Panobinostat, a histone deacetylase inhibitor, disrupts the HSP90/HDAC6 complex, which normally interacts with HIF-1α to prevent its degradation, thus blocking of complex formation induces HIF-1α degradation more rapidly [133].”
BackgroundQuantitative flux analysis reveals folate-dependent NADPH production
Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B., & Rabinowitz, J. D. (2014) · Nature · doi:10.1038/nature13236 · Cited by 1,114 · cited 1×
“PHGDH knockout reduces production of NADPH and increases ROS amount, resulting in increase of apoptosis [99].”
BackgroundDimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1
Jiang, B.-H., Rue, E., Wang, G. L., Roe, R., & Semenza, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17771 · Cited by 1,106 · cited 1×
“The basic regions upstream of the N-terminal of the HLH domain of both HIF-1α and HIF-1β subunits mediate the binding to the HRE of target gene promoters (Figure 1) [12].”
BackgroundGlucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
Le, A., Lane, A. N., Hamaker, M., Bose, S., Gouw, A., Barbi, J., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Zhang, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.009 · Cited by 1,095
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K., & Lu, Z. (2011) · Nature · doi:10.1038/nature10598 · Cited by 1,028
Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., & Fujii-Kuriyama, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4273 · Cited by 1,016
Pyruvate kinase M2 is a phosphotyrosine-binding protein
Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06667 · Cited by 995
Wise, D. R., Ward, P. S., Shay, J. E. S., Cross, J. R., Gruber, J. J., Sachdeva, U. M., Platt, J. M., DeMatteo, R. G., Simon, M. C., & Thompson, C. B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117773108 · Cited by 975
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940 · cited 1×
“Moreover, extracellular lactate-driven acidification promotes immune evasion by inhibiting activation and proliferation of CD4, CD8, NK, NKT, and dendritic cells, and by leading to apoptosis of CD8 lymphocytes and NK cells [56].”
BackgroundRaval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Walenta, S., Wetterling, M., Lehrke, M., Schwickert, G., Sundfør, K., Rofstad, E. K., & Mueller‐Klieser, W. (2000) · PubMed · Cited by 850
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
Hitosugi, T., Kang, S., Vander Heiden, M. G., Chung, T.-W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000431 · Cited by 784
Pyruvate Kinase M2 Regulates Gene Transcription by Acting as a Protein Kinase
Gao, X., Wang, H., Yang, J. J., Liu, X., & Liu, Z.-R. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.001 · Cited by 772
Gu, Y.-Z., Moran, S. M., Hogenesch, J. B., Wartman, L. D., & Bradfield, C. A. (1998) · Europe PMC (PubMed Central) · Cited by 771
NRF2 regulates serine biosynthesis in non–small cell lung cancer
DeNicola, G. M., Chen, P.-H., Mullarky, E., Sudderth, J. A., Hu, Z., Wu, D., Tang, H., Xie, Y., Asara, J. M., Huffman, K. E., et al. (2015) · Nature Genetics · doi:10.1038/ng.3421 · Cited by 746
Widespread, hypoxia‐inducible expression of HIF‐2α in distinct cell populations of different organs
Wiesener, M. S., Jürgensen, J. S., Rosenberger, C., Scholze, C., Hörstrup, J. H., Warnecke, C., Mandriota, S., Bechmann, I., Frei, U. A., Pugh, C. W., et al. (2003) · The FASEB Journal · doi:10.1096/fj.02-0445fje · Cited by 740
Kamphorst, J. J., Cross, J. R., Fan, J., de Stanchina, E., Mathew, R., White, E. P., Thompson, C. B., & Rabinowitz, J. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307237110 · Cited by 726
Targeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705
Chan, S. Y., Zhang, Y.-Y., Hemann, C., Mahoney, C. E., Zweier, J. L., & Loscalzo, J. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.015 · Cited by 702 · cited 1×
“This small RNA inhibits expression of iron–sulfur cluster assembly proteins (ISCU1 and ISCU2) required for Complex I assembly [109].”
BackgroundSuccinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer
King, A., Selak, M. A., & Gottlieb, E. (2006) · Oncogene · doi:10.1038/sj.onc.1209594 · Cited by 672
Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer
Chiche, J., Brahimi‐Horn, M. C., & Pouysségur, J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00994.x · Cited by 667
Bensaad, K., Favaro, E., Lewis, C. A., Peck, B., Lord, S., Collins, J. M., Pinnick, K. E., Wigfield, S., Buffa, F. M., Li, J.-L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.056 · Cited by 665
Serine is a natural ligand and allosteric activator of pyruvate kinase M2
Chaneton, B., Hillmann, P., Zheng, L., Martin, A. C. L., Maddocks, O. D. K., Chokkathukalam, A., Coyle, J. E., Jankevics, A., Holding, F. P., Vousden, K. H., et al. (2012) · Nature · doi:10.1038/nature11540 · Cited by 661
Mitochondrial composition and function under the control of hypoxia
Fuhrmann, D. C., & Brüne, B. (2017) · Redox Biology · doi:10.1016/j.redox.2017.02.012 · Cited by 643
Prabhakar, N. R., & Semenza, G. L. (2012) · Physiological Reviews · doi:10.1152/physrev.00030.2011 · Cited by 641
Transactivation and Inhibitory Domains of Hypoxia-inducible Factor 1α
Jiang, B.-H., Zheng, J. Z., Leung, S. W., Roe, R., & Semenza, G. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19253 · Cited by 629
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
Kane, R. C., Bross, P. F., Farrell, A. T., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-508 · Cited by 628
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 1×
“Other compounds belonging to cardiac glycosides [127], steroids [128], topoisomerase inhibitors [129], and microtubule binding agents [130] show the inhibitory effect of translation rate of HIF mRNA by different mechanisms.”
BackgroundLv, L., Li, D., Zhao, D., Lin, R., Chu, Y., Zhang, H., Zha, Z., Liu, Y., Li, Z., Xu, Y., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.04.025 · Cited by 610
Garcia, C. K., Goldstein, J. L., Pathak, R. K., Anderson, R. G. W., & Brown, M. S. (1994) · Cell · doi:10.1016/0092-8674(94)90361-1 · Cited by 587
Brizel, D. M., Schroeder, T., Scher, R. L., Walenta, S., Clough, R. W., Dewhirst, M. W., & Mueller-Klieser, W. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01630-3 · Cited by 586
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2543 · Cited by 566
Shukla, S. K., Purohit, V., Mehla, K., Gunda, V., Chaika, N. V., Vernucci, E., King, R. J., Abrego, J., Goode, G. D., Dasgupta, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.004 · Cited by 540
HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo
Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z. M., Felsher, D. W., Cheng, L., Pevsner, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.004 · Cited by 523
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508 · cited 1×
“doxorubicin, impair binding of HIF to chromatin, resulting in blocking of its transcriptional activity [146,147].”
BackgroundSmall molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism
Du, W., Zhang, L., Brett-Morris, A., Aguila, B., Kerner, J., Hoppel, C. L., Puchowicz, M., Serra, D., Herrero, L., Rini, B. I., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01965-8 · Cited by 468
Serine Catabolism Regulates Mitochondrial Redox Control during Hypoxia
Ye, J., Fan, J., Venneti, S., Wan, Y.-W., Pawel, B. R., Zhang, J., Finley, L. W. S., Lu, C., Lindsten, T., Cross, J. R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0250 · Cited by 452 · cited 2×
“Serine catabolism through one-carbon metabolism maintains this mitochondrial redox balance during hypoxia [100].”
BackgroundOn-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., et al. (2016) · Nature · doi:10.1038/nature19795 · Cited by 451
Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours
Garcia-Bermudez, J., Baudrier, L., La, K., Zhu, X. G., Fidelin, J., Sviderskiy, V. O., Papagiannakopoulos, T., Molina, H., Snuderl, M., Lewis, C. A., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0118-z · Cited by 442
Oxygen availability and metabolic adaptations
Nakazawa, M. S., Keith, B., & Simon, M. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.84 · Cited by 435
Chen, Z., Li, Y., Zhang, H., Huang, P., & Luthra, R. (2010) · Oncogene · doi:10.1038/onc.2010.193 · Cited by 426
Puisségur, M.-P., Mazure, N. M., Bertero, T., Pradelli, L., Grosso, S., Robbe-Sermesant, K., Maurin, T., Lebrigand, K., Cardinaud, B., Hofman, V, et al. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.119 · Cited by 423
In VivoExpression of mRNAs Encoding Hypoxia-Inducible Factor 1
Wiener, C. M., Booth, G., & Semenza, G. L. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1199 · Cited by 410
Qiu, B., Ackerman, D., Sanchez, D. J., Li, B., Ochocki, J. D., Grazioli, A., Bobrovnikova-Marjon, E., Diehl, J. A., Keith, B., & Simon, M. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1507 · Cited by 394
Favaro, E., Bensaad, K., Chong, M. G., Tennant, D. A., Ferguson, D. J. P., Snell, C., Steers, G., Turley, H., Li, J.-L., Günther, U. L., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.017 · Cited by 386
NDUFA4 Is a Subunit of Complex IV of the Mammalian Electron Transport Chain
Balsa, E., Marco, R., Perales-Clemente, E., Szklarczyk, R., Calvo, E., Landázuri, M. O., & Enríquez, J. A. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.07.015 · Cited by 383
Tello, D., Balsa, E., Acosta-Iborra, B., Fuertes-Yebra, E., Elorza, A., Ordóñez, Á., Corral-Escariz, M., Soro, I., López-Bernardo, E., Perales-Clemente, E., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.008 · Cited by 368
Huang, D., Li, T., Li, X., Zhang, L., Sun, L., He, X., Zhong, X., Jia, D., Song, L., Semenza, G. L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.028 · Cited by 352 · cited 1×
“HIF-1 suppresses the mitochondrial fatty acid oxidation through inhibition of mediumchain Acyl-CoA dehydrogenase (MCAD) and long-chain Acyl-CoA dehydrogenase (LCAD), resulting in reduction of ROS and suppression of the PTEN pathway, thus promoting tumor cell proliferation [64].”
BackgroundThe transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Albadari, N., Deng, S., & Li, W. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1613370 · Cited by 351
Sun, R. C., & Denko, N. C. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.022 · Cited by 344 · cited 1×
“The decreased entry of pyruvate into TCA cycle triggers a compensatory anaplerosis consisting in the increase of glutamine uptake through induction of glutamine transporters SLC1A5 and SNAT2/SLC38A2 [83,84].”
BackgroundRegulation of Metabolism by Hypoxia-Inducible Factor 1
Semenza, G. L. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010678 · Cited by 342
Mechanisms of metabolic dysfunction in cancer-associated cachexia
Petruzzelli, M., & Wagner, E. F. (2016) · Genes & Development · doi:10.1101/gad.276733.115 · Cited by 340
Favaro, E., Ramachandran, A., McCormick, R., Gee, H., Blancher, C., Crosby, M., Devlin, C., Blick, C., Buffa, F., Li, J.-L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010345 · Cited by 324 · cited 1×
“Decrease of ISCU induces ROS formation under hypoxia [110].”
BackgroundAllosteric inhibition of hypoxia inducible factor-2 with small molecules
Scheuermann, T. H., Li, Q., Ma, H.-W., Key, J., Zhang, L., Chen, R., Garcia, J. A., Naidoo, J., Longgood, J., Frantz, D. E., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1185 · Cited by 315
T cell metabolic fitness in antitumor immunity
Siska, P. J., & Rathmell, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.007 · Cited by 312
Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0463 · Cited by 309
Triglycerides Promote Lipid Homeostasis during Hypoxic Stress by Balancing Fatty Acid Saturation
Ackerman, D., Tumanov, S., Qiu, B., Michalopoulou, E., Spata, M., Azzam, A., Xie, H., Simon, M. C., & Kamphorst, J. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.015 · Cited by 305
Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1766-x · Cited by 303 · cited 1×
“Promising results are expected from other approved HDAC inhibitors: romidepsin [136], belinostat [137], panobinostat [138], and chidamide [139].”
BackgroundWood, S. M., Gleadle, J. M., Pugh, C. W., Hankinson, O., & Ratcliffe, P. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15117 · Cited by 292
Maynard, M. A., Qi, H., Chung, J., Lee, E. H. L., Kondo, Y., Hara, S., Conaway, R. C., Conaway, J. W., & Ohh, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208681200 · Cited by 283
Hara, S., Hamada, J., Kobayashi, C., Kondo, Y., & Imura, N. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5659 · Cited by 282
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance
Xiong, G., Stewart, R. L., Chen, J., Gao, T., Scott, T. L., Samayoa, L. M., O’Connor, K., Lane, A. N., & Xu, R. (2018) · Nature Communications · doi:10.1038/s41467-018-06893-9 · Cited by 274
Mylonis, I., Chachami, G., Samiotaki, M., Panayotou, G., Paraskeva, E., Kalousi, A., Georgatsou, E., Bonanou, S., & Simos, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605058200 · Cited by 266
ATP-citrate lyase is essential for macrophage inflammatory response
Infantino, V., Iacobazzi, V., Palmieri, F., & Menga, A. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.037 · Cited by 265
Self-citationVorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., He, K., Sridhara, R., Abraham, S., Booth, B. P., Verbois, L., Morse, D. E., Jee, J. M., Pope, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2672 · Cited by 262
Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool
Iacobazzi, V., Castegna, A., Infantino, V., & Andria, G. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.07.012 · Cited by 230
Self-citationPayen, V. L., Porporato, P. E., Baselet, B., & Sonveaux, P. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2098-5 · Cited by 220
Belinostat: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0275-8 · Cited by 216
Lee, J., Kim, H. K., Han, Y.-M., & Kim, J. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.11.009 · Cited by 214
Oxygen availability and metabolic reprogramming in cancer
Xie, H., & Simon, M. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.799973 · Cited by 206
Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
Goyal, P., Weissmann, N., Grimminger, F., Hegel, C., Bader, L., Rose, F., Fink, L., Ghofrani, H. A., Schermuly, R. T., Schmidt, H. H. H. W., et al. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.02.071 · Cited by 192
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.002 · Cited by 190
Lipid desaturation – the next step in targeting lipogenesis in cancer?
Peck, B., & Schulze, A. (2016) · The FEBS Journal · doi:10.1111/febs.13681 · Cited by 189
Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2116 · Cited by 187
Miranda, E., Nordgren, I. K., Male, A. L., Lawrence, C. E., Hoakwie, F., Cuda, F., Court, W., Fox, K. R., Townsend, P. A., Packham, G. K., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja402993u · Cited by 185
Hypoxia rapidly activates HIF‐3α mRNA expression
Heidbreder, M., Fröhlich, F., Jöhren, O., Dendorfer, A., Qadri, F., & Dominiak, P. (2003) · The FASEB Journal · doi:10.1096/fj.02-0963fje · Cited by 182
Glucose, glycolysis and lymphocyte responses
Donnelly, R. P., & Finlay, D. K. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.07.034 · Cited by 182
Hypoxia causes triglyceride accumulation via HIF-1-mediated stimulation of lipin 1 expression
Mylonis, I., Sembongi, H., Befani, C. D., Liakos, P., Siniossoglou, S., & Simos, G. (2012) · Journal of Cell Science · doi:10.1242/jcs.106682 · Cited by 179
The Human Hypoxia-Inducible Factor 1α Gene:HIF1AStructure and Evolutionary Conservation
Iyer, N. V., Leung, S. W., & Semenza, G. L. (1998) · Genomics · doi:10.1006/geno.1998.5416 · Cited by 176
Oncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 173
Chen, J., Zhao, S., Nakada, K., Kuge, Y., Tamaki, N., Okada, F., Wang, J., Shindo, M., Higashino, F., Takeda, K., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63924-7 · Cited by 170
Gimm, T., Wiese, M., Teschemacher, B., Deggerich, A., Schödel, J., Knaup, K. X., Hackenbeck, T., Hellerbrand, C., Amann, K., Wiesener, M. S., et al. (2010) · The FASEB Journal · doi:10.1096/fj.10-159806 · Cited by 166
Leite, T. C., Coelho, R. G., Silva, D. D., Coelho, W. S., Marinho-Carvalho, M. M., & Sola-Penna, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.11.009 · Cited by 165
Ader, I., Brizuela, L., Bouquerel, P., Malavaud, B. A., & Cuvillier, O. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0917 · Cited by 164
Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., & Ganjoo, K. N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3660 · Cited by 155 · cited 1×
“The nitroimidazole mustard evofosfamide (TH-302) is the most advanced HAP, and it is in phase III trials for pancreatic adenocarcinoma and soft tissue sarcoma [168,169].”
BackgroundPasanen, A., Heikkilä, M. M., Rautavuoma, K., Hirsilä, M., Kivirikko, K. I., & Myllyharju, J. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.04.008 · Cited by 153
Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia
Zhang, X., Saarinen, A. M., Hitosugi, T., Wang, Z., Wang, L., Ho, T. H., & Liu, J. (2017) · eLife · doi:10.7554/elife.31132 · Cited by 152
Characterisation of the active/de-active transition of mitochondrial complex I
Babot, M., Birch, A., Labarbuta, P., & Galkin, A. S. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.02.018 · Cited by 148
Higd1a is a positive regulator of cytochrome c oxidase
Hayashi, T., Asano, Y., Shintani, Y., Aoyama, H., Kioka, H., Tsukamoto, O., Hikita, M., Shinzawa‐Itoh, K., Takafuji, K., Higo, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419767112 · Cited by 140
The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity
Vatrinet, R., Leone, G., Luise, M. D., Girolimetti, G., Vidone, M., Gasparre, G., & Porcelli, A. M. (2017) · Cancer & Metabolism · doi:10.1186/s40170-017-0165-0 · Cited by 140
Befani, C. D., Vlachostergios, P. J., Hatzidaki, E., Patrikidou, A., Bonanou, S., Simos, G., Papandreou, C. N., & Liakos, P. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0805-8 · Cited by 135
Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer
Morotti, M., Bridges, E., Valli, A., Choudhry, H., Sheldon, H., Wigfield, S., Gray, N., Zois, C. E., Grimm, F., Jones, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818521116 · Cited by 131
Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in vivo
Lee, S., McIntyre, D. J. O., Honess, D. J., Hulı́ková, A., Pacheco‐Torres, J., Cerdán, S., Swietach, P., Harris, A. L., & Griffiths, J. R. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0216-5 · Cited by 128
Yamashita, T., Ohneda, O., Nagano, M., Iemitsu, M., Makino, Y., Tanaka, H., Miyauchi, T., Goto, K., Ohneda, K., Fujii‐Kuriyama, Y., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01332-07 · Cited by 118
EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1
Thomas, S. L., Zhong, D., Zhou, W., Malik, S., Liotta, D. C., Snyder, J. P., Hamel, E., & Giannakakou, P. (2008) · Cell Cycle · doi:10.4161/cc.6410 · Cited by 117
Cancer heterogeneity is not compatible with one unique cancer cell metabolic map
Strickaert, A., Saiselet, M., Dom, G., Deken, X. D., Dumont, J. E., Féron, O., Sonveaux, P., & Maenhaut, C. (2016) · Oncogene · doi:10.1038/onc.2016.411 · Cited by 112
Okazaki, A., Gameiro, P. A., Christodoulou, D. C., Laviolette, L. A., Schneider, M., Chaves, F. L., Stemmer-Rachamimov, A. O., Yazinski, S. A., Lee, R. E., Jr., Stephanopoulos, G. N., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87800 · Cited by 112
TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma
Todisco, S., Convertini, P., Iacobazzi, V., & Infantino, V. (2019) · Cancers · doi:10.3390/cancers12010068 · Cited by 112
Self-citationTerzuoli, E., Puppo, M., Rapisarda, A., Uranchimeg, B., Cao, L., Burger, A. M., Ziche, M., & Melillo, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1075 · Cited by 111
Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease
Jones, R., & Morris, M. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.418 · Cited by 111
VHLinactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment
Rathmell, W. K., & Chen, S. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.1.63 · Cited by 105
Romidepsin for Cutaneous T-cell Lymphoma
Prince, H. M., & Dickinson, M. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3144 · Cited by 103
Siniossoglou, S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.09.014 · Cited by 101
Metabolic Routes in Inflammation: The Citrate Pathway and its Potential as Therapeutic Target
Infantino, V., Pierri, C. L., & Iacobazzi, V. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180510124558 · Cited by 101
Self-citationPham, E., Birrer, M. J., Eliasof, S. D., Garmey, E. G., Lazarus, D. D., Lee, C. R., Man, S., Matulonis, U. A., Peters, C. G., Xu, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2810 · Cited by 95
NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma
Lai, R. K., Xu, M., Chiu, D. K., Tse, A. P., Wei, L. L., Law, C., Lee, D. P. H., Wong, C., Wong, M. P., Ng, I. O., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1987 · Cited by 95
Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer
Jia, X.-Q., Zhang, S., Zhu, H., Wang, W., Zhu, J., Wang, X., & Qiang, J. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.03.006 · Cited by 91
Lee, S., Jee, J., Bae, J., Liu, K., & Lee, Y. M. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24813 · Cited by 86
Li, P., Zhang, D., Shen, L., Dong, K., Wu, M., Ou, Z., & Shi, D. (2016) · Scientific Reports · doi:10.1038/srep22831 · Cited by 84
Mylonis, I., Kourti, M., Samiotaki, M. K., Panayotou, G., & Simos, G. (2016) · Journal of Cell Science · doi:10.1242/jcs.195339 · Cited by 84
Lee, W.-N. P., Guo, P., Lim, S., Bassilian, S., Lee, S. T., Boren, J., Cascante, M., Go, V. L. W., & Boros, L. G. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602243 · Cited by 83
Triantafyllou, E.-A., Georgatsou, E., Mylonis, I., Simos, G., & Paraskeva, E. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.06.015 · Cited by 80
Iacobazzi, V., Infantino, V., Castegna, A., & Andria, G. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.07.016 · Cited by 72
Self-citationMaier, A., Wu, H., Cordasic, N., Oefner, P. J., Dietel, B., Thiele, C., Weidemann, A., Eckardt, K., & Warnecke, C. (2017) · The FASEB Journal · doi:10.1096/fj.201700235r · Cited by 71
GL331 inhibits HIF-1α expression in a lung cancer model
Chang, H., Shyu, K., Lee, C.-C., Tsai, S.-C., Wang, B.-W., Lee, Y. H., & Lin, S. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00111-6 · Cited by 66
Acute L ‐glutamine deprivation compromises VEGF‐a upregulation in A549/8 human carcinoma cells
Drogat, B., Bouchecareilh, M., North, S., Petibois, C., Déléris, G., Chevet, É., Bikfalvi, A., & Moenner, M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21044 · Cited by 63
Wardman, P., Dennis, M. F., Everett, S. A., Patel, K. B., Stratford, M. R. L., & Tracy, M. (1995) · Biochemical Society Symposia · doi:10.1042/bss0610171 · Cited by 59
Infantino, V., Dituri, F., Convertini, P., Santarsiero, A., Palmieri, F., Todisco, S., Mancarella, S., Giannelli, G., & Iacobazzi, V. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.018 · Cited by 57
Self-citationKim, K. H., Kim, D., Park, J. Y., Jung, H. J., Cho, Y., Kim, H. K., Han, J., Choi, K., & Kwon, H. J. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1235-1 · Cited by 53
Sun, N.-Y., & Yang, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00792 · Cited by 53
Chronic hypoxia alters mitochondrial composition in human macrophages
Fuhrmann, D. C., Wittig, I., Heide, H., Dehne, N., & Brüne, B. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.09.023 · Cited by 51
Hypoxia-adaptive pathways: A pharmacological target in fibrotic disease?
Strowitzki, M. J., Ritter, A. S., Kimmer, G., & Schneider, M. A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104364 · Cited by 48
Coordinate regulation of stress signaling and epigenetic events by Acss2 and HIF-2 in cancer cells
Chen, R., Xu, M., Nagati, J. S., & Garcia, J. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0190241 · Cited by 42
Pappalardi, M. B., McNulty, D. E., Martin, J. D., Fisher, K. E., Jiang, Y., Burns, M. C., Zhao, H., Ho, T. F., Sweitzer, S. M., Schwartz, B., et al. (2011) · Biochemical Journal · doi:10.1042/bj20101201 · Cited by 41
Ways into Understanding HIF Inhibition
Schönberger, T., Fandrey, J., & Prost-Fingerle, K. (2021) · Cancers · doi:10.3390/cancers13010159 · Cited by 41
Kourti, M., Ikonomou, G., Giakoumakis, N.-N., Rapsomaniki, M., Landegren, U. D., Siniossoglou, S., Lygerou, Z., Simos, G., & Mylonis, I. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.02.017 · Cited by 38
Pang, Y., Yang, C., Schovanek, J., Wang, H., Bullova, P., Caisova, V., Gupta, G., Wolf, K. I., Semenza, G. L., Zhuang, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16224 · Cited by 37
Exploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologies
Kyle, H. F., Wickson, K. F., Stott, J., Burslem, G. M., Breeze, A. L., Tiede, C., Tomlinson, D. C., Warriner, S. L., Nelson, A. S., Wilson, A. J., et al. (2015) · Molecular BioSystems · doi:10.1039/c5mb00284b · Cited by 37
MgcRacGAP Interacts with HIF-1α and Regulates its Transcriptional Activity
Lyberopoulou, A., Venieris, E., Mylonis, I., Chachami, G., Pappas, I. S., Simos, G., Bonanou, S., & Georgatsou, E. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110460 · Cited by 36
Contracting the ‘mus cells’– does down‐sizing suit us for diving into the memory pool?
Kurtuluş, S., Tripathi, P., Opferman, J. T., & Hildeman, D. A. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00920.x · Cited by 35
Zhang, J., Wei, H., Aiping, D., Qi, Y., & Shulan, Z. (2013) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182a0c068 · Cited by 34
Cheng, T., Grasse, L., Shah, J. J., & Chandra, J. (2015) · Drugs of today · doi:10.1358/dot.2015.51.8.2362311 · Cited by 32
Göttgens, E., van den Heuvel, C. N. A. M., de Jong, M. C., Kaanders, J. H. A. M., Leenders, W. P. J., Ansems, M., Bussink, J., & Span, P. N. (2019) · Cancers · doi:10.3390/cancers11121971 · Cited by 32
Convertini, P., Todisco, S., Santis, F. D., Pappalardo, I., Iacobazzi, D., Morelli, M. A. C., Fondufe‐Mittendorf, Y. N., Martelli, G., Palmieri, F., & Infantino, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081888 · Cited by 31
Self-citationGkotinakou, I., Kechagia, E., Pazaitou‐Panayiotou, K., Mylonis, I., Liakos, P., & Tsakalof, A. K. (2020) · Cells · doi:10.3390/cells9112440 · Cited by 31
Conformation‐specific crosslinking of mitochondrial complex I
Ciano, M., Fuszard, M., Heide, H., Botting, C. H., & Galkin, A. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.02.039 · Cited by 29
Huang, Y.-C., Huang, F.-I., Mehndiratta, S., Lai, S.-C., Liou, J., & Yang, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4068 · Cited by 28
Specific inhibition of HIF activity: can peptides lead the way?
Mylonis, I., Chachami, G., & Simos, G. (2021) · Cancers · doi:10.3390/cancers13030410 · Cited by 21
Imayoshi, N., Yoshioka, M., Chauhan, J., Nakata, S., Toda, Y., Fletcher, S., Strovel, J. W., Takata, K., & Ashihara, E. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.088 · Cited by 20
Hetherington, K., Hegedüs, Z., Edwards, T. A., Sessions, R. B., Nelson, A. S., & Wilson, A. J. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000417 · Cited by 15
Wang, Y., Thompson, J., & Chan, W. K. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.02.003 · Cited by 9
Cited by
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome
Lv, R., Liu, X., Zhang, Y., Dong, N., Wang, X., He, Y., Yue, H., & Yin, Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01496-3 · Cited by 477
The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer
Fontana, F., Giannitti, G., Marchesi, S., & Limonta, P. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.89942 · Cited by 280
Keoh, L. Q., Chiu, C.-F., & Ramasamy, T. S. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10956-y · Cited by 66
Metabolic reprogramming: The driving force behind cancer drug resistance
El-Sehrawy, A. A. M. A., Hsu, C.-Y., Alkhathami, A. G., Chandra, M., Basunduwah, T. S., Malathi, H., Senapati, J. N., Gautam, A., Kadhem, M., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152392 · Cited by 11
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771365 · Cited by 11
Metadata
- Authors
- Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-05-27
- Volume
- 22
- Issue
- 11
- Pages
- 5703
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3164014129
- Cited by
- 499
- References
- 170
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.